<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053673</url>
  </required_header>
  <id_info>
    <org_study_id>RBN-2397-19-001</org_study_id>
    <nct_id>NCT04053673</nct_id>
  </id_info>
  <brief_title>RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study</brief_title>
  <official_title>A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ribon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ribon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins&#xD;
      in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the&#xD;
      cell from sending a signal (Type 1 interferon) that tells the immune system that something is&#xD;
      wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth&#xD;
      and also shuts down the &quot;don't kill me&quot; signal the tumor is sending to evade the immune&#xD;
      system. As a PARP7 inhibitor RBN-2397 is different from drugs inhibiting PARP1, PARP2 and&#xD;
      PARP3 enzymes which are approved for the treatment of certain ovarian and breast cancers.&#xD;
&#xD;
      The primary purpose of this study is to determine the maximum tolerated dose (MTD) of orally&#xD;
      administered RBN-2397 in patients with advanced or metastatic solid tumors. This study will&#xD;
      also evaluate the safety and tolerability of RBN-2397, examine the pharmacokinetics (PK)&#xD;
      (measure how the body absorbs, breaks down and eliminates RBN-2397) and investigate whether&#xD;
      it has antitumor activity in solid tumor cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, Phase 1, multi-center, open-label, dose-escalation study to:&#xD;
&#xD;
        -  Evaluate the safety profile and MTD of RBN-2397 administered orally and establish the&#xD;
           RBN-2397 dose(s) and schedule(s) recommended for further investigation in Phase 2&#xD;
&#xD;
        -  Characterize the PK profile of RBN-2397&#xD;
&#xD;
        -  Identify preliminary antitumor activity.&#xD;
&#xD;
        -  Biomarkers and their correlation with response to RBN-2397 and other outcomes will be&#xD;
           examined.&#xD;
&#xD;
      Cohorts will follow a traditional 3 + 3 design. After enrollment of the first participant&#xD;
      within a cohort, there must be a wait period of at least 1 week before enrollment of&#xD;
      additional participants in that cohort.&#xD;
&#xD;
      After the MTD is determined, Expansion Cohort(s) of approximately 20 participants each will&#xD;
      be enrolled to further examine the safety, PK, pharmacodynamics, and antitumor activity of&#xD;
      RBN-2397 at the MTD or other dose recommended for further investigation. Based on nonclinical&#xD;
      data as well as clinical data obtained from the dose-escalation portion of this study,&#xD;
      enrollment in the Expansion Cohort(s) may be limited to specific tumor type(s), as warranted&#xD;
      by the data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>through study completion (an average of one year)</time_frame>
    <description>Frequency of Dose limiting Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>through study completion (an average of one year)</time_frame>
    <description>Grade and frequency of adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration</measure>
    <time_frame>Through Study Day 22</time_frame>
    <description>Area-under-the-curve (AUC inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration</measure>
    <time_frame>Through Study Day 22</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity that may be associated with RBN-2397 treatment assessed by CT/MRI Response Evaluation Criteria for Solid Tumors (RECIST) Criteria v1.1</measure>
    <time_frame>Every 6-8 weeks; through study completion (an average of one year)</time_frame>
    <description>Objective response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity that may be associated with RBN-2397 treatment</measure>
    <time_frame>Every 6-8 weeks; through study completion (an average of one year)</time_frame>
    <description>Disease control rate (DCR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>RBN-2397</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Multiple doses of RBN-2397 for oral administration Dose Expansion: Oral dose of RBN-2397 as determined during Dose Escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBN-2397</intervention_name>
    <description>an oral PARP7 Inhibitor</description>
    <arm_group_label>RBN-2397</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic or advanced-stage solid malignant tumor (which may include &quot;solid&quot; lymphoma&#xD;
             [e.g., mantle cell]) for whom no therapy exists that would be curative or might&#xD;
             provide clinical benefit.&#xD;
&#xD;
          -  Male or female aged â‰¥18 years.&#xD;
&#xD;
          -  Must agree to undergo tumor biopsy&#xD;
&#xD;
          -  Normal organ and bone marrow function&#xD;
&#xD;
          -  Patient and his/her partner agree to use adequate contraception during and for 3&#xD;
             months after the last study drug dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to swallow oral medications&#xD;
&#xD;
          -  Major surgery within 4 weeks of starting study&#xD;
&#xD;
          -  Pregnant or breast-feeding.&#xD;
&#xD;
          -  Receiving intravenous antibiotics for an active infection&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or hepatitis B or C infection.&#xD;
&#xD;
          -  History of a different malignancy unless disease-free for at least 5 years&#xD;
&#xD;
          -  Some medications are not allowed while on study. Interested participants will need to&#xD;
             inform study doctor of all the medications he/she is taking.&#xD;
&#xD;
          -  Herbal medicines, and grapefruit, grapefruit juice, pomegranate juice, star fruit or&#xD;
             orange marmalade (made with Seville oranges) are not allowed to be taken during study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa L Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennessee Oncology, PLLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations Manager</last_name>
    <phone>617-475-7203</phone>
    <email>clinicaltrials@ribontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Parsons</last_name>
      <phone>720-848-4603</phone>
      <email>aaron.parsons@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Schenk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI-Denver/HealthOne</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Falchook, MD</last_name>
      <phone>281-221-0693</phone>
      <email>Gerald.Falchook@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Falchook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Dunning</last_name>
      <phone>203-785-4267</phone>
      <email>Haley.dunning@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia LoRusso, DO, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI-Sarasota/Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Patel, MD</last_name>
      <phone>941-377-9993</phone>
      <email>mpatel@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Smith</last_name>
      <phone>617-643-5965</phone>
      <email>ssmith164@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Dejan Juric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fiorentino</last_name>
      <phone>617-632-5485</phone>
      <email>amandam_fiorentino@dcfi.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI-Nashville/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson, MD</last_name>
      <phone>615-329-7274</phone>
      <email>mjohnson@tnonc.com</email>
    </contact>
    <investigator>
      <last_name>Melissa L. Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy A Yap, MD, PhD</last_name>
      <phone>713-563-1784</phone>
      <email>tyap@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Timothy A Yap, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cohen MS, Chang P. Insights into the biogenesis, function, and regulation of ADP-ribosylation. Nat Chem Biol. 2018 Feb 14;14(3):236-243. doi: 10.1038/nchembio.2568. Review.</citation>
    <PMID>29443986</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>PARP7 inhibition</keyword>
  <keyword>First in Human</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

